Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Olga A. Antonova
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Anastasia D. Sokol
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Kseniia A. Deinichenko
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Polina G. Kazakova
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Mikhail M. Milovanov
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Alexander V. Zakubansky
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Alexandra I. Akinshina
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Anastasia V. Tsypkina
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Svetlana V. Romanova
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Vladimir E. Muhin
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Sergey I. Mitrofanov
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Vladimir S. Yudin
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Sergey M. Yudin
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Antonida V. Makhotenko
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Anton A. Keskinov
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Sergey A. Kraevoy
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Ekaterina A. Snigir
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Dmitry V. Svetlichnyy
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia
Veronika I. Skvortsova
The Federal Medical Biological Agency (FMBA of Russia), 30 Volokolamskoe sh., Moscow 125310, Russia
The coronavirus disease 2019 (COVID-19) is accompanied by a cytokine storm with the release of many proinflammatory factors and development of respiratory syndrome. Several SARS-CoV-2 lineages have been identified, and the Delta variant (B.1.617), linked with high mortality risk, has become dominant in many countries. Understanding the immune responses associated with COVID-19 lineages may therefore aid the development of therapeutic and diagnostic strategies. Multiple single-cell gene expression studies revealed innate and adaptive immunological factors and pathways correlated with COVID-19 severity. Additional investigations covering host–pathogen response characteristics for infection caused by different lineages are required. Here, we performed single-cell transcriptome profiling of blood mononuclear cells from the individuals with different severity of the COVID-19 and virus lineages to uncover variant specific molecular factors associated with immunity. We identified significant changes in lymphoid and myeloid cells. Our study highlights that an abundant population of monocytes with specific gene expression signatures accompanies Delta lineage of SARS-CoV-2 and contributes to COVID-19 pathogenesis inferring immune components for targeted therapy.